- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2024 Financial Results | 134 | GlobeNewswire (Europe) | BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the third quarter ended September 30, 2024, and provided an... ► Artikel lesen | |
| 07.11. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 09.08. | Ikena Oncology GAAP EPS of -$0.28 | 2 | Seeking Alpha | ||
| 08.08. | Ikena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial Results | 110 | GlobeNewswire (Europe) | BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update... ► Artikel lesen | |
| 12.07. | Ikena Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Ikena Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.05. | Ikena further sheds staff and pipeline in bid to maximise value | 1 | Pharmaceutical Technology | ||
| 29.05. | Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing' | 1 | Benzinga.com | ||
| 29.05. | Wedbush downgrades Ikena, cites discontinuation of lead asset | 1 | Seeking Alpha | ||
| 29.05. | Pre-market Movers: Cheche Group, AERWINS Technologies, Siyata Mobile, Surmodics, Ikena Oncology | 533 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheche Group Inc. (CCG) is up over 58% at $2.11.
Siyata... ► Artikel lesen | |
| 29.05. | Ikena to cut workforce by 53%, explore strategic options (update) | 1 | Seeking Alpha | ||
| 29.05. | Ikena Oncology, Inc. Announces Strategic Update | 191 | GlobeNewswire (Europe) | Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring... ► Artikel lesen | |
| 28.05. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Ikena Oncology, Inc.: Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update | 213 | GlobeNewswire (Europe) | Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and... ► Artikel lesen | |
| 12.03. | Ikena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results | 270 | GlobeNewswire (Europe) | IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in... ► Artikel lesen | |
| 21.02. | Ikena Oncology, Inc.: Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer | 210 | GlobeNewswire (Europe) | Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy... ► Artikel lesen | |
| 18.01. | Ikena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate Updates | 383 | GlobeNewswire (Europe) | IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 10,500 | +0,29 % | Aktien Frankfurt: Dax nähert sich wieder Rekordhoch | FRANKFURT (dpa-AFX) - Anleger haben am Montag Mut geschöpft und den Dax in Richtung seines bisherigen Rekordes getrieben. Der deutsche Leitindex stieg gegen Mittag um 1,31 Prozent auf 19.467,76 Punkte.... ► Artikel lesen | |
| EPIGENOMICS | 1,010 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOGEN | 149,05 | -1,94 % | Samsung Bioepis, Biogen Get European Commission Approval For Opuviz, A Biosimilar To Aflibercept | WESTON (dpa-AFX) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.Opuviz... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,924 | +3,70 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| MAINZ BIOMED | 0,220 | -2,87 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest der nächsten Generation für den globalen Markt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest... ► Artikel lesen | |
| VIKING THERAPEUTICS | 45,850 | -2,59 % | What the Options Market Tells Us About Viking Therapeutics | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -4,46 % | Defence Therapeutics Inc. begrüßt Dr. Svetlana Selivanova, Expertin für Radiopharmazeutika, im Board of Directors | Vancouver, BC, Kanada, 13. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das
"Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches Unternehmen... ► Artikel lesen | |
| CENTOGENE | 0,120 | +471,43 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 3,000 | -10,18 % | Affimed N.V.: Affimed Reports Third Quarter 2024 Financial Results & Business Update | AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a... ► Artikel lesen | |
| GALAPAGOS NV | 25,800 | +1,57 % | Galapagos NV: Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 | New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,710 | -3,93 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,491 | +12,10 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen |
Das Unternehmen IKENA ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,40 % bei einem Aktienkurs von 1,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKENA ONCOLOGY INC finden Sie auf Wallstreet Online.
